Can Medtronic’s (MDT) Core Units Keep Up With Management’s New Bets?
Medtronic (MDT) is focusing on accelerating growth through innovation platforms, strong core segments, and high-growth opportunities like robotic surgery and new devices. The company's recent collaboration with Cornerstone Robotics and a revised fiscal 2027 outlook signal a bullish future, with projected organic revenue growth of 7.25% to 7.75%. However, Medtronic faces intense competition from companies like Johnson & Johnson and Intuitive Surgical in these targeted growth markets, which could challenge its ability to capture significant market share.
How New TREMFYA Data At Johnson & Johnson Stock Has Changed Its Investment Story
Johnson & Johnson's recent clinical data for TREMFYA in axial psoriatic arthritis and CARVYKTI in multiple myeloma reinforce its focus on high-value specialty medicines to counter pressures from patent expirations and litigation. While these results strengthen the company's pipeline and oncology portfolio, the core investment challenge remains the rapid integration of new therapies to maintain earnings resilience. Analysts anticipate significant revenue and earnings growth by 2029, though alternative scenarios suggest even higher potential based on the performance of key products like CAPLYTA.
Johnson & Johnson (NYSE:JNJ) Declares Quarterly Dividend, Extending Decades-Long Streak
Johnson & Johnson (NYSE:JNJ) has declared another quarterly dividend, extending its streak of annual increases to over six decades. This consistent cash distribution is supported by the company's diversified healthcare operations, spanning pharmaceuticals and medical technology, which provide stable cash generation across economic cycles. The move reinforces JNJ's reputation for reliability, making it an attractive stock for cash-focused investors.
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics announced the submission of an application to the European Medicines Agency (EMA) by Johnson & Johnson for icotrokinra, an investigational oral peptide for moderate-to-severe plaque psoriasis in adults and adolescents. The submission is based on four Phase 3 studies that met all primary and co-primary endpoints, demonstrating significant skin clearance and a favorable safety profile. Icotrokinra is designed to selectively block the IL-23 receptor and has shown superiority against deucravacitinib in trials.
Adicet Bio (NASDAQ:ACET) Stock Moved Up to "Hold" by Wall Street Zen
Wall Street Zen has upgraded Adicet Bio (NASDAQ:ACET) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $46.80. The clinical-stage biotechnology company's shares opened up 9.1% at $9.02, despite missing its latest earnings estimate. Institutional investors and hedge funds own a significant 83.89% of the company.
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - What's Next?
Protagonist Therapeutics (NASDAQ:PTGX) shares gapped up before trading, opening at $141.81. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $147.13, and recently exceeded quarterly expectations with significant year-over-year revenue growth. Despite strong institutional ownership, insiders have sold a substantial amount of stock in the last quarter.
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
This article compares two dividend aristocrats, AbbVie (ABBV) and Johnson & Johnson (JNJ), to determine which is a better investment over the next decade, particularly for retirees. While AbbVie offers higher growth and a cheaper multiple, Johnson & Johnson is presented as the more stable choice due to its diversified revenue streams, strong balance sheet, and lower risk profile, especially for those dependent on dividend income. AbbVie faces patent cliffs and a leveraged balance sheet, making J&J a more secure option for income-focused investors.
Johnson & Johnson Clinical Trials Show Progress Across Key Therapies
Johnson & Johnson announced positive results from clinical trials for its therapies, Tremfya and Carvykti. Tremfya met primary and secondary endpoints in treating psoriatic arthritis with axial involvement, while Carvykti showed five-year progression-free remissions in relapsed or refractory multiple myeloma patients. These findings highlight advancements in treating inflammatory diseases and certain cancers.
What Bristol Myers Squibb Stock’s Strong Buy Upgrade Means For Shareholders
Bristol-Myers Squibb recently released positive two-year Phase 3 data for Sotyktu in psoriatic arthritis, expanded access to ZENBEXUS, and affirmed a quarterly dividend of US$0.63. These updates contribute to a "Strong Buy" upgrade, reinforcing the company's immunology pipeline, specialty oncology distribution, and commitment to shareholder returns. Despite forecasted revenue and earnings declines due to patent expiries, the company's new products and financial management are key to offsetting these challenges and suggest a potential 8% upside to its current price.
PepsiCo stock hits 52-week low at 127.55 USD
PepsiCo's stock has hit a 52-week low of $127.64, a 4.7% decline over the past year, despite being considered undervalued with an attractive P/E ratio of 16.82 and a PEG ratio of 0.43 according to InvestingPro data. The company maintains strong fundamentals, including a 54% gross profit margin and a 53-year history of dividend increases, now yielding 4.62%. Recent developments include adjusted price targets from BNP Paribas Exane and TD Cowen, the appointment of Joaquin Duato to its board, and the decision to remove weight-loss drugs from employee health plans due to rising costs.
J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
Johnson & Johnson and Legend Biotech's CAR T therapy, Carvykti, demonstrated significant long-term survival benefits for multiple myeloma patients, with half remaining alive and progression-free after at least five years in a Phase 2 study. The CARTITUDE-2 study Cohort A, involving 20 patients, showed a 69.2% overall survival rate at a median of 60.7 months, further solidifying Carvykti's efficacy in patients who have received prior treatments. While two new deaths occurred since the last data cutoff, none were attributed to Carvykti, and Gilead is preparing to challenge Carvykti with its own CAR T therapy, anito-cel.
Rx Rundown: Lilly, Bristol Myers Squibb, Johnson & Johnson and more
This article provides a weekly rundown of significant medical marketing news, deal-making, FDA approvals, funding, and industry chatter involving major pharmaceutical companies. Key highlights include Eli Lilly's FDA approval for a once-weekly basal insulin, Bristol Myers Squibb and Johnson & Johnson announcing job cuts, and various strategic collaborations and financial activities across the healthcare sector.
Two Wilson County Grads Turn a Night Class Into Jobs at Johnson & Johnson's New Biologics Plant
Two Wilson County graduates, Zy’Ques Ingram and Dillon Gay, have secured jobs as bio-manufacturing production technicians at Johnson & Johnson's new biologics plant after completing a BioWork certificate program. This success highlights the collaborative efforts between the North Carolina Biotechnology Center, Wilson Community College, and Wilson County Schools to create a skilled workforce for the region's growing life sciences industry. Wilson Community College is further bolstering these efforts with a new $36.4 million Biomanufacturing Education & Skills Training Center, demonstrating a commitment to providing high-paying job opportunities within the BioPharma Crescent.
Johnson & Johnson Reports TREMFYA STAR Trial Results
Johnson & Johnson (NYSE:JNJ) announced that its drug TREMFYA successfully met primary and major secondary endpoints in the Phase 4 STAR study for axial psoriatic arthritis. The study demonstrated significant improvements in patient-reported disease activity, axial symptoms, and MRI-measured sacroiliac-joint inflammation at Week 24. The safety profile of TREMFYA remained consistent with no new safety signals identified.
J&J's TREMFYA improved spinal pain and stiffness in a 411-person study
Johnson & Johnson announced that its drug TREMFYA (guselkumab) met primary and major secondary endpoints in the Phase 4 STAR study for axial psoriatic arthritis (PsA). The study showed significant improvement in spinal pain and stiffness, and reduction in MRI-confirmed sacroiliac joint inflammation in biologic-naïve adults. This marks TREMFYA as the first IL-23 inhibitor to demonstrate such improvements in a dedicated study for axial PsA.
Johnson & Johnson (JNJ) Phase 3 Myeloma Data Recasts Long Term Survival Expectations
Johnson & Johnson (JNJ) released new Phase 3 MajesTEC-3 results for TECVAYLI plus DARZALEX FASPRO in relapsed/refractory multiple myeloma, showing durable disease control and improved survival outcomes. The data suggests a potential for some patients to achieve survival patterns similar to the general population, with modeling indicating an 86.6% projected cure fraction for overall survival. This strengthens J&J's oncology narrative, potentially impacting regulatory decisions, treatment guidelines, and future revenue mix for the pharmaceuticals segment.
€110.9 million in cash, but a wider first-half loss for Nanobiotix (NBTX).
Nanobiotix reported a wider net loss of €34.3 million for the first half of 2026, compared to €5.4 million in the same period of 2025, largely due to a significant decrease in revenue following a one-off payment in the previous year and higher interest costs on financing. Despite this, the company's cash and cash equivalents stood at €110.9 million, projected to fund operations for over 12 months, boosted by €80.1 million in net proceeds from a global offering in May 2026. Nanobiotix continues to advance its JNJ-1900 (NBTXR3) development, with updated Phase 2 data showing positive responses in lung cancer, and is expanding its Nanoprimer and Neurological disease platforms.
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Legend Biotech announced five-year follow-up data from its CARTITUDE-2 Cohort A study for CARVYKTI (ciltacabtagene autoleucel; cilta-cel) in patients with relapsed/refractory multiple myeloma (RRMM). The data, presented at the 2026 International Myeloma Society (IMS) Annual Meeting, showed that 50% of patients remained alive and progression-free five years after a single infusion without maintenance therapy. This suggests that earlier use of CARVYKTI could lead to durable treatment-free remission and strengthens evidence for its curative potential.
Nanobiotix Q2FY27 Results: Net loss widens to €34.3m on revenue drop
Nanobiotix reported a widened net loss of €34.3 million in H1 2026, primarily due to a significant drop in revenue from €26.6 million to €5.6 million. This revenue decline was largely attributed to a one-off non-cash impact from the previous year. Despite the increased net loss, the company strengthened its cash position to €110.9 million and advanced its clinical pipeline, with lead candidate JNJ-1900 showing positive results in NSCLC studies.
Why Welltower Stock Topped the Market on Thursday
Welltower (NYSE: WELL) shares rose on Thursday after a J.P. Morgan analyst upgraded the healthcare REIT to "overweight" with a price target of $260, citing positive prospects and better-than-average growth. Despite this positive outlook and the company's strong performance in senior housing, its dividend yield of 1.5% is considered low compared to other REITs. The article suggests that while Welltower is a good company, more lucrative investment opportunities may exist elsewhere in the REIT sector.
Apollo’s Johnson & Johnson Deal Could Open a New Healthcare Growth Avenue
Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's DePuy Synthes orthopaedics unit for nearly $20 billion. This potential deal would allow Apollo to expand its healthcare investments, while J&J could streamline its MedTech portfolio to focus on higher-growth, higher-margin areas. Both companies face distinct bull and bear cases regarding this transaction, with Apollo gaining a stable asset and J&J gaining immediate liquidity for M&A and R&D.
A Hedge Fund Rolls the Dice on Ultragenyx
Shares of Ultragenyx Pharmaceutical Inc. rose significantly after the FDA approved Fayuvi, its gene therapy for Sanfilippo syndrome Type A. Investment firm Sofinnova Investments, a large shareholder, had filed a Freedom of Information Act (FOIA) request with the FDA about Ultragenyx’s manufacturing compliance ahead of the approval decision. This action highlights how investment professionals use FOIA requests as a strategic tool to assess regulatory risks and market uncertainties surrounding drug approvals.
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Contineum Therapeutics' partnered drug, JNJ-5120/PIPE-307, developed with Johnson & Johnson, failed its primary efficacy endpoint in a Phase 2 trial for major depressive disorder. While the drug showed no new safety signals and J&J is still analyzing broader data, the missed endpoint casts doubt on the program's future. Contineum's other internally developed programs, like PIPE-791, remain unaffected by this outcome.
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Contineum Therapeutics' partnered drug JNJ-5120/PIPE-307, developed with Johnson & Johnson, failed to meet its primary endpoint in a Phase 2 trial for major depressive disorder. While the drug was well-tolerated with no new safety signals, the lack of efficacy raises questions about its future. Johnson & Johnson is continuing to analyze the broader dataset before making a decision, leaving the program's fate unresolved for now.
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
NANOBIOTIX has provided an update on its operational progress and financial results for the first half of 2026. The company reported promising early results from its Phase 1 NSCLC study and the Johnson & Johnson-led Phase 2 CONVERGE study for JNJ-1900 (NBTXR3), along with an acceptable safety profile. Financially, NANOBIOTIX strengthened its position with an €86 million offering, extending its cash runway into 2029, and reported €110.9 million in cash and cash equivalents as of June 30, 2026.
Aurora Innovation Announces Analyst and Investor Day Event in Dallas with SEC Filing
Aurora Innovation, Inc. announced via an SEC Form 8-K filing that it hosted an Analyst and Investor Day in Dallas, Texas on September 23, 2026. The company provided a press release and presentation materials to comply with Regulation FD, ensuring public disclosure of information shared during the event. David Maday, CFO, signed the report, confirming the company's Class A common stock trades on Nasdaq under AUR, with redeemable warrants trading as AUROW.
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
This article compares two major pharmaceutical companies, Pfizer and AbbVie, analyzing their financial performance, pipeline prospects, and market valuations to determine which stock is a better investment. While Pfizer is diversifying its portfolio beyond COVID-19 products and building strong oncology and obesity pipelines, it faces a significant patent cliff. AbbVie has successfully navigated the loss of exclusivity for Humira with new immunology drugs and is expanding through strategic acquisitions, showing more visible growth in the near term.
Eli Lilly and Co Stock (LLY) Moved Up by 3.73% on Sep 24: A Full Analysis
Eli Lilly and Co (LLY) stock rose by 3.73% due to the FDA approval of its once-weekly basal insulin Onswik for type 2 diabetes, reinforcing its leadership in diabetes care. The company also saw positive investor reaction to strong commercial traction in its metabolic franchise and plans for a new multi-billion-dollar manufacturing facility. Analyst commentary and upward price target revisions further supported the stock's upward momentum.
Twist Bioscience Corp Stock (TWST) Moved Up by 11.04% on Sep 24: A Full Analysis
Twist Bioscience Corp (TWST) saw an 11.04% stock increase on September 24, driven by a strategic collaboration with Eli Lilly, integrating Twist's data services into Lilly's AI-driven drug discovery platform. This partnership, coupled with strong third-quarter financial results showing double-digit revenue growth and improved margins, has generated significant investor interest and positive analyst sentiment. Despite this growth, the company faces risks such as persistent net losses, a high valuation, and recent insider share liquidations.
What J&J’s Spravato patent win could mean for psychedelic drugs
Johnson & Johnson's recent patent victory for its depression treatment Spravato could set a precedent for intellectual property protection in the burgeoning psychedelic drug market. The case involved J&J defending patents related to methods and formulations of esketamine, a derivative of ketamine, against a generic competitor. This outcome has significant implications for companies developing psychedelic-based therapies, as it suggests that patent protection can extend to new uses, formulations, and delivery methods of existing compounds, even those with long histories of use.
Nanobiotix stock breaks through its support at €29.66 and drops 23.5% over one month
Nanobiotix, a Parisian biotech company, has seen its stock drop by 23.71% over the past month, breaking below its support level of €29.66. Despite positive clinical results for its lung cancer treatment published recently, the stock continues its downward trend. However, its performance over the last year remains strong with a 152.3% gain, indicating high volatility.
Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?
Intuitive Surgical's stock has dropped 29% this year due to slowing procedure growth for its da Vinci robots, increased competition, and expiring ACA subsidies. Despite these headwinds, many analysts believe the sell-off is overdone, with a majority rating the stock as "buy" or "strong buy" and foreseeing significant upside due to long-term market potential and an aging demographic. Historically, similar declines have proven to be good buying opportunities for the medical device company.
Envestnet Asset Management Inc. Has $513.60 Million Stock Holdings in Merck & Co., Inc. $MRK
Envestnet Asset Management Inc. significantly increased its stake in Merck & Co., Inc. during the second quarter, now holding nearly 4 million shares valued at $513.6 million. Institutional investors collectively own 76.07% of Merck, reflecting strong confidence. Analysts generally maintain a "Moderate Buy" rating with an average price target of $154.24, following Merck exceeding its recent quarterly earnings and revenue estimates.
Citigroup Adjusts Price Target on PepsiCo to $142 From $145, Maintains Neutral Rating
Citigroup has adjusted its price target for PepsiCo (NASDAQ:PEP) to $142, down from $145, while maintaining a Neutral rating on the stock. This update comes as part of ongoing analyst evaluations of the non-alcoholic beverage and snack giant. The article also provides a company profile, recent news, and other analyst opinions related to PepsiCo.
Can Johnson & Johnson (JNJ) Justify A Discount To Cash Flow?
This article examines whether Johnson & Johnson's current share price of US$269 is justified by its future cash flow using a Discounted Cash Flow (DCF) model. The model suggests that JNJ may be undervalued as its intrinsic value is estimated to be meaningfully above its current price, supported by strong free cash flow generation and positive clinical trial data. The article also presents bull and bear narratives, offering different perspectives on the company's valuation based on growth prospects and current market sentiment.
FDA warns that certain Impella heart pump controllers may need serviced
The FDA has issued an early alert regarding new safety issues with specific Impella Automated Impella Controllers (AICs) from Johnson & Johnson MedTech. These devices require hardware, firmware, and/or software updates to address potential problems like the failure to recognize purge cassettes or unreliable buttons, though no serious injuries or deaths have been linked to these issues yet. Affected AICs can still be used for patient care while awaiting service, and this alert adds to a history of multiple recalls for the Impella platform.
Zymeworks Completes Acquisition of Theravance Biopharma
Zymeworks Inc. has completed its previously announced acquisition of Theravance Biopharma, integrating the company to further its strategy of becoming a diversified revenue-generating biotechnology company. This move combines innovative R&D with growing commercial and royalty-based cash flows. Zymeworks will host a conference call on September 28 to discuss the final transaction details.
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie (NYSE:ABBV)
This article analyzes Johnson & Johnson (JNJ) and AbbVie (ABBV) in the 2H 2026 healthcare dividend roundup, highlighting JNJ's justified premium over ABBV due to its stronger balance sheet, lower payout ratio, and superior capital allocation flexibility. The author argues that JNJ's defensive profile is bolstered by its conservative financials and recent legal resolution, despite trading at a higher P/E multiple. The analysis suggests JNJ is a more compelling investment for long-term growth and income investors.
Telerobotic surgery is advancing around the world. Will the US embrace it?
Telerobotic surgery is rapidly advancing globally, with procedures already performed in various countries for conditions like stroke, heart disease, and cancer. While the technology promises to expand access to specialized care, particularly in underserved areas, its widespread adoption in the US faces hurdles including regulatory approvals, credentialing, licensing across states, and reimbursement models. Major medical device companies are investing in the technology, but challenges remain in building trust, ensuring network reliability, and integrating it into existing clinical workflows.
Florida AG sues PBMs, pharmas over rise in insulin prices
Florida Attorney General James Uthmeier has filed a lawsuit against three major drug manufacturers—Eli Lilly, Novo Nordisk, and Sanofi—along with three large pharmacy benefit managers (PBMs)—CVS Caremark, Express Scripts, and Optum Rx. The lawsuit alleges that these companies colluded to inflate insulin prices, with drugmakers setting high prices and then paying significant rebates to PBMs for formulary placement, thereby ensuring mutual profit from the rising costs. This legal action mirrors a previous lawsuit by the Federal Trade Commission against PBMs and group purchasing organizations regarding insulin pricing practices.
Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now
The global minimally invasive robotic surgical system market is projected to reach $18.15 billion by 2030, growing from $8.9 billion in 2025 due to increased precision, patient outcomes, and adoption in outpatient facilities. Key growth drivers include improved reimbursement, precision medicine, and demand for minimally invasive procedures. Product innovation and strategic acquisitions by major players like Intuitive Surgical, Johnson & Johnson, and Medtronic are strengthening the market, with North America currently the largest regional market and Asia-Pacific expected to be the fastest-growing.
J&J says analysis demonstrates potential of Tecvayli-Darzalex combo for multiple myeloma
A new analysis of phase 3 data from Johnson & Johnson suggests that a combination of Tecvayli and Darzalex Faspro could be a promising treatment for multiple myeloma patients. This combination was effective for patients who had already undergone up to three prior therapies.
Five safe monthly dividend stocks favored by Boomers show steady payouts and growth in September 2026.
Five monthly dividend stocks favored by Boomer investors, including Realty Income, Agree Realty, STAG Industrial, Main Street Capital, and Gladstone Investment, have demonstrated reliable income streams and growth in September 2026. These companies maintained or raised their dividends, supported by strong cash flow and diverse income sources across various sectors. The stocks offer attractive yields, making them appealing for income-focused investors looking to build a stable monthly paycheck.
Nvidia’s Immense Dividend Hike Puts Dividend Growth Stocks in the Spotlight
Nvidia recently announced a significant dividend increase of 2,400%, raising its quarterly payout to $0.25 per share. While this makes Nvidia one of the largest dividend payers, analysts note that the dividend yield remains low relative to its financial health, with share buybacks still being the primary method of returning cash to shareholders. This move, along with strong performance from other dividend growth stocks, highlights a broader trend of companies increasing dividends and suggests a diversifying market beyond the "Magnificent Seven."
The Premium On Abbott Laboratories Keeps Growing. So Does The Case For Stryker and Boston Scientific
Abbott Laboratories (ABT) trades at a premium valuation compared to its faster-growing rivals, Stryker (SYK) and Boston Scientific (BSX), despite slower operating income growth. Abbott's diversified business and confident forecast support its valuation, while its peers offer more focused growth and higher margins at lower price-to-operating-income ratios. Investors face a decision between Abbott's stability and its competitors' more aggressive growth profiles, with Abbott's second-half performance critical to validating its premium.
Is Pfizer (PFE) Getting Too Pricey After Its 24% Rise?
Pfizer's stock has risen 23.9% over the past year, leading to questions about its current valuation relative to earnings. With a P/E ratio of 36.7x, it trades above the pharmaceuticals industry average, and its shares appear overvalued based on Simply Wall St's Fair Ratio benchmark. Future profitability expectations are also influenced by a new agreement to share overseas pricing revenue with the US Department of Health and Human Services.
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH
This article compares two healthcare ETFs: Invesco's Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Healthcare ETF (IYH). IBBQ offers a more concentrated, biotech-focused, high-risk, high-reward investment with a lower expense ratio and higher one-year return, while IYH provides broader exposure to the entire healthcare sector, higher dividend yield, and more stability for conservative investors. The choice between the two depends on an investor's risk tolerance and investment goals.
AC Immune SA (ACIU) Stock Price, News, Quote & History
This article provides comprehensive financial information for AC Immune SA (ACIU), including its stock price, historical data, key financial metrics, and analyst insights. AC Immune SA is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, with a pipeline of drugs and diagnostics targeting conditions like Alzheimer's and Parkinson's. The company's stock showed a 5.34% gain at the time of reporting.
Stryker Corporation $SYK Shares Bought by State Street Corp
State Street Corp increased its stake in Stryker Corporation by 1.2% in the second quarter, now owning 15.5 million shares valued at approximately $4.9 billion. Institutional investors collectively hold 77.09% of SYK stock. Despite recent insider selling, analysts maintain a "Moderate Buy" rating for Stryker, which recently reported strong quarterly earnings and issued optimistic FY 2026 EPS guidance.
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Andra AP fonden
Andra AP fonden significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 583.2% in the second quarter, now holding 28,912 shares valued at $18 million. Institutional investors collectively own 83.31% of the company. Regeneron recently reported strong quarterly earnings, beating consensus estimates with $14.29 EPS and $4.29 billion in revenue, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $802.18, despite recent insider share sales.
